Skip to main content

Akero Therapeutics, Inc.

AKRODelisted Dec 9, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001744659

Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 267 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 2:09 PM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Akero Therapeutics, Inc., annual
Line itemFY2024FY2023FY2022FY2021FY2020
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Filing10-K10-K10-K10-K10-K
ReportedJan 27, 2025Feb 29, 2024Mar 17, 2023Feb 25, 2022Mar 16, 2021
Research and development$247.5M$141.8M$85.3M$81.8M$64.9M
Selling, general and administrative$37.9M$31.1M$29.9M$19.1M$15.2M
Operating income-$285.4M-$172.9M-$115.2M-$100.9M-$80.2M
Interest expense$4.67M$3.10M$739.0K––
Net income-$252.1M-$151.8M-$112.0M-$100.8M-$79.2M
EPS, basic$-3.75$-2.89$-2.87––
EPS, diluted$-3.75$-2.89$-2.87$-2.89–
Weighted shares, basic67.1M52.6M39.0M––
Weighted shares, diluted67.1M52.6M39.0M34.8M–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Akero Therapeutics, Inc., annual
Line itemFY2024FY2023FY2022FY2021FY2020
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Filing10-K10-K10-K10-K10-K
ReportedJan 27, 2025Feb 29, 2024Mar 17, 2023Feb 25, 2022Mar 16, 2021
Cash and equivalents$340.2M$234.2M$249.8M$150.5M$187.2M
Short-term investments$402.8M$315.8M$101.7M$37.8M$81.1M
Total current assets$770.4M$560.0M$355.2M$193.6M$271.3M
Property, plant and equipment–$18.0K$47.0K$90.0K$131.0K
Total assets$825.9M$580.3M$356.6M$195.5M$273.3M
Accounts payable$9.03M$7.04M$7.97M$6.71M$3.43M
Total current liabilities$39.8M$19.1M$19.1M$25.1M$13.1M
Total liabilities$75.8M$45.0M$30.0M$26.4M$14.6M
Shareholders' equity$750.1M$535.3M$326.6M$169.1M$258.7M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Akero Therapeutics, Inc., annual
Line itemFY2024FY2023FY2022FY2021FY2020
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Filing10-K10-K10-K10-K10-K
ReportedJan 27, 2025Feb 29, 2024Mar 17, 2023Feb 25, 2022Mar 16, 2021
Operating cash flow-$230.1M-$145.4M-$92.5M-$79.7M-$70.8M
Capital expenditures––––$148.0K
Free cash flow––––-$71.0M
Stock-based compensation$29.7M$21.5M$23.2M$10.1M$6.02M
Investing cash flow-$109.7M-$223.6M-$63.8M$42.3M-$9.76M
Financing cash flow$445.8M$353.3M$255.6M$602.0K$203.1M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Akero Therapeutics, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 3, 202582.3M+17.9%SEC
Jul 31, 202580.0M+15.2%SEC
May 1, 202579.7M+15.3%SEC
Feb 14, 202579.6M+41.4%SEC
Oct 31, 202469.8M+25.3%SEC
Aug 2, 202469.4M+24.9%SEC
May 3, 202469.2M+38.1%SEC
Feb 23, 202456.3M+19.9%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.